Healthcare IT Today May 16, 2022
Healthcare IT News

With a focus on evidence-generating medicine, Osmind brings scientific rigor to the medical community focused on advanced interventions for moderate to severe mental health conditions, including ketamine therapy, SPRAVATO®, psychedelic medicine, and neuromodulation such as TMS

Osmind, the public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, today announced a $40 million Series B investment led by DFJ Growth. The Series B round brings the total amount of funding for Osmind to $57 million since the company’s founding in 2020. Justin Kao, partner at DFJ Growth, and the co-founder of Helix, will join the Osmind Board of Directors.

In addition to DFJ Growth, the round includes new investors Susa Ventures,...

Today's Sponsors

SalesSparx
Canton & Company
Curation Health

Today's Sponsors

Amwell
Oliver Wyman

Today's Sponsor

Canton & Company

 
Topics: Investments, Mental Health, Provider, Trends
Mental Health Services drop by 23% for Children with Medicaid Coverage
122: The 5 root causes of behavioral health inequity
These 14 innovations are tackling youth mental health challenges
Panel Calls for Integrated Care, Physician Training to Combat Rising Mental Health and Addiction Epidemic
UHS Reduces Earnings Outlook 19% — Behavioral Health Patient Volume, Workforce Woes Continue